Erythrocytes do not activate purified and platelet soluble guanylate cyclases even in conditions favourable for NO synthesis

Stepan Gambaryan1,2,5*, Hariharan Subramanian3, Linda Kehrer4, Igor Mindukshev2, Julia Sudnitsyna2, Cora Reiss5, Natalia Rukoyatkina2, Andreas Friebe4, Iraida Sharina6, Emil Martin6 and Ulrich Walter5,7

Abstract

Background: Direct interaction between Red blood cells (RBCs) and platelets is known for a long time. The bleeding time is prolonged in anemic patients independent of their platelet count and could be corrected by transfusion of RBCs, which indicates that RBCs play an important role in hemostasis and platelet activation. However, in the last few years, opposing mechanisms of platelet inhibition by RBCs derived nitric oxide (NO) were proposed. The aim of our study was to identify whether RBCs could produce NO and activate soluble guanylate cyclase (sGC) in platelets.

Methods: To test whether RBCs could activate sGC under different conditions (whole blood, under hypoxia, or even loaded with NO), we used our well-established and highly sensitive models of NO-dependent sGC activation in platelets and activation of purified sGC. The activation of sGC was monitored by detecting the phosphorylation of Vasodilator Stimulated Phosphoprotein (VASP S239) by flow cytometry and Western blot. ANOVA followed by Bonferroni’s test and Student’s t-test were used as appropriate.

Results: We show that in the whole blood, RBCs prevent NO-mediated inhibition of ADP and TRAP6-induced platelet activation. Likewise, coincubation of RBCs with platelets results in strong inhibition of NO-induced sGC activation. Under hypoxic conditions, incubation of RBCs with NO donor leads to Hb-NO formation which inhibits sGC activation in platelets. Similarly, RBCs inhibit activation of purified sGC, even under conditions optimal for RBC-mediated generation of NO from nitrite.

Conclusions: All our experiments demonstrate that RBCs act as strong NO scavengers and prevent NO-mediated inhibition of activated platelets. In all tested conditions, RBCs were not able to activate platelet or purified sGC.

Keywords: Erythrocytes, Nitric oxide, Soluble guanylate cyclase, Platelets, Hemoglobin

Plain English summary

The main role of RBCs in the human body is to transport O2 from lungs to different tissues and CO2 back to lungs. Recently studies propose that RBCs, under certain conditions, can produce NO and inhibit platelet activation. Nitric Oxide soluble Guanylate Cyclase/cyclic guanosine monophosphate/protein kinase G (NO/sGC/cGMP/PKG) pathway is one of the most powerful mechanisms responsible for platelet inhibition. However, the activation of platelet sGC/cGMP/PKG by NO released from RBCs was not directly proven.

Therefore, the main aim of our work was to test whether RBCs can release NO that can stimulate platelet sGC. Incubating RBCs with purified sGC and platelets under normal and hypoxic conditions, did not induce sGC activation indicating that NO is not released from RBCs under tested conditions. Rather, externally added NO onto whole blood was scavenged by RBCs, thereby preventing sGC activation in platelets. Our data strongly indicate that RBCs do not release biologically active NO
that is sufficient to activate platelet sGC, which is a highly sensitive NO receptor.

Background
Red blood cells (RBCs) and platelets represent the major cell population in mammalian blood. Functional interactions between RBCs and platelets are known for a long time from clinical observations. The bleeding time is prolonged in patients with anemia independent on their platelet count and could be corrected by RBCs transfusion, and bleeding defects are directly connected with platelet function but not with the blood coagulation system [1–3]. On the other hand, RBCs transfusion could increase platelet activation and might be dangerous in treatment of coronary artery diseases [4]. These clinical observations clearly pointed out that RBCs, by still unidentified mechanism(s), play some important role in platelet activation. However, recently in several papers [5–9] platelet inhibition by RBCs-derived NO was described. In all these papers, platelet inhibition by deoxygenated RBCs, that can reduce nitrite to NO was shown. Importantly, in none of these papers direct activation of platelet soluble Guanylate Cyclase (sGC) by RBCs-derived NO was shown. In papers where the inhibition of platelet function by nitrite/RBCs was described [5–9], platelet activation was assessed by aggre-gometry and flow cytometry, which is not sufficient to confirm whether the inhibition was due to the activation of NO/cGMP pathway in platelets. Several publications described direct NO production from RBCs by endothelial NO synthase (eNOS) [10, 11], but other studies did not find any functionally active NOS in RBCs [12]. The direct activation of platelet sGC by RBCs was never shown before. Hence, the connection between RBCs, eNOS and hemoglobin (Hb) to platelet sGC activation and platelet inhibition cannot be proven.

Hb and RBCs are involved in the modulation of NO signaling and metabolism. Since the discovery of NO as a signaling molecule, numerous studies proposed the formation of the nitrosyl-heme adduct of Hb (NO-Hb), a source of bioavailable NO. The nitrosylation of conserved cysteine of Hb β-chain (β93Cysteine) by NO and the formation of S-Nitrosohemoglobin (SNO-Hb) were proposed as putative mechanisms for Hb functioning as NO carrier [13, 14]. These interactions between NO and Hb are superseded by the fast reaction between NO and oxyhemoglobin (oxyHb). According to mathematical modelling and experimental data, most of NO in the blood is annihilated by the fast irreversible reaction of oxyHb with NO, which yields oxidized Hb (methemoglobin, metHb) and nitrate [15]. On the other hand, deoxyhemoglobin (deoxy-Hb) may act as a nitrite reductase, promoting the synthesis of NO from inorganic nitrite [16, 17].

The high affinity NO receptor, sGC mediates most of the biological functions of NO, especially at low NO concentrations [18, 19]. Although different reactions between NO and Hb were established, the mechanisms of NO/SNO release from Hb are not well understood. It is less clear how NO can be released from RBCs under physiologic conditions of overwhelming excess of free Hb. It remains to be proved that RBCs-derived NO can activate platelet sGC.

Endogenous NO is a well-known and potent inhibitor of platelet activation (reviewed in [20, 21]). NO-dependent inhibition of platelets is solely mediated by sGC [22]. Intact platelet sGC is highly sensitive to endogeneous NO and even nanomolar NO concentrations are sufficient for cGMP generation [23]. In platelets, Protein Kinase G (PKG), which phosphorylates multiple substrates responsible for platelet inhibition, is the major downstream target of cGMP [21]. For evaluation of platelet sGC activity, we developed a highly sensitive method, based on NO/sGC/cGMP/PKG dependent phosphorylation of vasodilator-stimulated phosphoprotein (VASP) in human platelets, which has been used in numerous studies [20]. Most studies that report NO release from RBCs had been performed using blood vessel relaxation experiments or with isolated washed RBCs. However, both approaches were not sufficient to answer the question whether RBCs can produce biologically active NO/SNO. Vasorelaxation is a complex process controlled not only by NO, but also by a number of other vasodilators. Moreover, the experiments with isolated RBCs never demonstrated that NO or other reactive nitrogen species generated by RBCs result in activation of sGC.

In this report, we directly addressed this question by determining the sGC-dependent signaling in intact platelets and the activation of purified sGC. Our data clearly showed that RBCs, under the tested conditions, cannot activate platelet sGC or purified sGC, but in contrast, they act as a potent NO scavengers.

Methods
Materials
DEA-NO (Biomol, Hamburg, Germany), iloprost (Ilomedin; Schering, Berlin, Germany), Thrombin Receptor Activating Peptide-6 (TRAP-6) (Bachem, Weil am Rhein, Germany) were purchased. Antibody against actin, L-arginine, L-N^δ-Nitroarginine methyl ester (L-NAME), NG-Methyl-L-arginine (L-NMA), and phenylephrine were obtained from Sigma (Munich, Germany). The PAC-1-FITC and CD-41-FITC antibodies were obtained from BD-Bioscience (Heidelberg, Germany). Antibodies against VASP (Ser^239) were from Nano Tools (Teningen, Germany). sGC and PKG I antibodies were described previously [24, 25].
Preparation of human platelets, white blood cells (WBCs) and RBCs

Human platelets were prepared as reported previously [26]. Blood was collected from healthy volunteers, and WBCs were isolated by Leucosep tubes (Greiner, Frickenhausen, Germany) according to the manufacturer’s instructions. WBC concentration was adjusted to 6×10^6/ml. RBCs were collected after separation of PRP and washed thrice with HEPES buffer; the supernatant from the last wash was used as control to confirm the absence of free Hb. For experiments with RBCs, suspensions which did not contain free hemoglobin were used.

Platelet aggregation

Aggregation in whole blood was measured by Multiplate (Roche Diagnostics, Mannheim, Germany), in PRP and washed platelets by Apact4004 (LabiTec, Ahrensburg, Germany) aggregometers. Citrated whole blood was preincubated with sodium nitroprusside (SNP) and aggregation was initiated by ADP (10 μM). PRP and washed platelets were preincubated for 1 min with SNP or iloprost and aggregation was initiated by ADP.

FACS analysis

FACS analysis was performed using a Becton Dickinson FACS Calibur with CELL Quest software, version 3.1f (Becton Dickinson, Heidelberg, Germany). Platelets in the whole blood were identified by CD41 staining. Washed platelets concentration was adjusted to 3×10^8/ml and for washed platelets/RBC mixture 4.5×10^9/ml washed RBCs were added to platelet suspension. All samples after stimulation were directly fixed with 3 % formaldehyde. The samples were incubated with PAC-1-FITC, or CD41-FITC antibodies and analysed by FACS. For phospho-VASP, the samples were permeabilized with 0.2 % Triton X-100.

Western blot analysis

Samples were lysed with Laemmli buffer and the proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane as described [27]. Membranes were incubated with primary antibodies overnight at 4 °C. Goat anti-rabbit or anti-mouse IgG conjugated with horseradish peroxidase were used as secondary antibodies followed by ECL detection. Blots were analysed densitometrically using NIH Image J software for uncalibrated optical density.

Experiments with deoxygenated washed platelets and RBCs

HEPES buffer was degassed under vacuum and bubbled with argon. This buffer was used for washing and resuspension of washed platelets and RBCs. RBCs and platelets were further bubbled with argon and kept under argon in closed gas-tight tubes. Then, RBCs were washed 3 times with argon-saturated HEPES to wash out free hemoglobin from lysed RBCs. In some experiments deoxy-RBCs were incubated with DEA-NO and/or with NaNO2 prior addition to platelet suspension. For experiments with purified sGC, preparations of deoxy-RBC were also transferred into an anaerobic glove chamber (Model 110 V, Coy Laboratory Products, Inc.) and equilibrated for additional 2 h in anaerobic environment.

Spectral analysis of Hb

To confirm the Hb status of RBCs, UV spectra were taken for oxy-Hb, and deoxy-Hb after incubation with NO donor, 10 μl of RBC were lysed in hypoosmotic media (HEPES buffer diluted by water to 50 mOsm), and the visible absorption spectra in the 450–700 nm range were immediately collected on a UV–vis Spectrophotometer (SPECS SSP-715, Spectroscopy Systems, Russia).

sGC activity assay

Full-length human sGC was expressed in insect Sf9 cells as described previously [28]. Recombinant sGC was purified using anion exchange and Ni-affinity chromatography as detailed previously [29]. Anaerobic sGC was prepared in an anaerobic train as described previously, [19] and transferred into the anaerobic glove chamber. Enzymatic sGC activity was assayed using a modified [α-32P]GTP to [32P]cGMP conversion assay [30] with buffers prepared anaerobically and equilibrated in the anaerobic chamber overnight. To measure NO-induced activity, 0.01 μg sGC in 10 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM DTT, 3 mM MgCl2, was incubated with indicated RBCs or buffer prior to exposure to the mixture containing NO donor (DEA-NO) and GTP. To determine if RBCs generate any bioavailable NO from nitrite, anaerobic RBCs were incubated at 37 °C for 15 s or 5 min with indicated amount of nitrite, prior to the addition to 0.1 μg sGC. The cGMP-forming reaction was initiated by 1 mM GTP/[α-32P]GTP (~100,000 cpm). The reaction was stopped by zinc carbonate precipitation and processed following the protocol established previously [30].

Data analysis

All experiments were performed at least thrice, and data are expressed as means±SEM. Differences between groups were analyzed by ANOVA followed by Bonferroni’s
test and Student’s *t*-test as appropriate. *p < 0.05* was considered statistically significant.

**Results**

**RBCs prevent NO donor-mediated platelet response**

Inhibition of platelet aggregation by RBCs-generated NO was reported in several publications [5, 7, 11, 31]. To test whether RBCs influence platelet aggregation, we measured ADP-triggered aggregation in whole blood, PRP, and washed platelets. In whole blood, very high (50 and 100 µM) concentrations of Sodium nitroprusside (SNP) were required for partial inhibition of platelet aggregation (25 ± 4 and 32 ± 6 %, respectively). On the contrary, in PRP and washed platelets, 0.5 µM SNP was sufficient to achieve similar degrees of inhibition. Activation of cAMP/Protein Kinase A (PKA) signaling by iloprost (5 nM) completely inhibited platelet aggregation in all the three preparations (Fig. 1a). Corroborating the aggregation studies, NO donor (DEA-NO) significantly inhibited TRAP-6 induced integrin (αIIbβ3) activation in PRP and washed platelets, but not in whole blood or in washed platelets incubated with washed RBCs. Iloprost, used as a positive control in these experiments, completely prevented integrin αIIbβ3 activation (Fig. 1b). To prove that the platelet inhibitory response was mediated by PKG and PKA activation, we measured VASP phosphorylation on the same sets of experiments. DEA-NO only slightly (1.7 ± 0.3 fold) increased VASP phosphorylation in the whole blood samples, whereas in PRP and washed platelets the increase of VASP phosphorylation was more than 25-fold and comparable with the iloprost-induced response. Coincubation of washed platelets with washed RBCs completely prevented DEA-NO-induced VASP phosphorylation (Fig. 2a). It was recently [31] reported that in RBCs, activation of eNOS by L-arginine has an inhibitory effect on platelet aggregation. However, this study did not determine whether the inhibition is due to the activation of sGC/cGMP/PKG pathway in platelets. To address this issue, we incubated the whole blood with L-arginine or NOS inhibitor (L-NAME) and measured platelet VASP phosphorylation by FACS analysis. Neither inhibition, nor stimulation of NOS in whole blood affected VASP phosphorylation (Fig. 2b).

**Presence of RBCs prevents NO-induced PKG activation in platelets**

In the next series of experiments, we examined whether longer incubation of RBCs with platelets activates platelet PKG. We also assessed the RBC concentration necessary to inhibit NO-dependent activation of PKG. Since VASP phosphorylation by PKG is the primary parameter evaluated in this set of studies, we first tested by Western blotting whether the key elements of the NO/cGMP pathway downstream of eNOS are detectable in RBCs. The lysate from 10⁹/ml platelets exhibited a strong signal for sGC, PKG and VASP. In contrast, these proteins were not detected in RBCs (10⁹/ml) (Fig. 3a).

Next, we observed that incubation of RBCs with platelets in suspension for up to 30 min does not increase the phosphorylation of VASP. Corroborating aggregation experiments, the strong phosphorylation of VASP induced by DEA-NO was completely abolished by RBC (Fig. 3b). The titration of RBCs demonstrated that even 10⁹ RBCs/ml, which is ~50-fold lower than the physiological RBC count, were sufficient to prevent NO-induced phosphorylation of VASP in platelets (Fig. 3c). Neither inhibition, nor stimulation of NOS in RBCs
affected PKG activation in platelets (Fig. 3d), which fits in line with the results from whole blood (Fig. 2b).

sGC is a very sensitive receptor for NO, which evolved to respond to nanomolar concentrations of NO [32]. While oxyhemoglobin is a very efficient NO scavenger, the affinity of oxygen-free hemoglobin for NO is comparable to sGC. It was previously shown that deoxygenated RBCs can produce S-nitroso-L-cystein (L-SCNO) and S-nitrosoglutathione (GSNO) [33]. Therefore, we tested whether deoxygenated RBCs affect NO-dependent activation of purified sGC and platelet sGC/PKG pathway. Exogenously added L-CSNO and GSNO are strong activators of purified and platelet sGC (data not shown). However, presence of deoxygenated RBCs had no effect on purified sGC activity and only inhibited DEA-NO-induced sGC activation (Fig. 3e). Similar results were observed, if RBCs were incubated with DEA-NO prior to the addition to sGC (data not shown).

Because of the high NO scavenging properties of free Hb [34], special care was taken to assure that the RBC suspensions did not contain free Hb as a result of haemolysis. In all our experiments, we used supernatant from RBCs as a control for the absence of free Hb. In contrast to the addition of RBCs, supernatant from RBCs added to the platelet suspension had no effect on DEA-NO-induced VASP phosphorylation. Also, RBCs and supernatant of RBCs had no influence on PKA-induced VASP phosphorylation stimulated by iloprost (Fig. 4a). Platelet cGMP levels are affected not only by the elevation of cGMP through sGC activation, but also by the inhibition of cGMP-degrading phosphodiesterases. Phosphodiesterase 5 (PDE5) is the main PDE responsible for cGMP degradation in platelets [21]. Therefore, we tested whether RBCs may cause inhibition of PDE5 in platelets. The PDE5 inhibitor sildenafil induced similar VASP phosphorylation in platelet suspension with and without added RBCs (Fig. 4b) indicating that platelet PDE5 was not affected by RBCs.

Neither deoxygenation, nor addition of nitrate promote RBC-induced sGC activation

The nitrate-nitrite-NO reductive pathway is an alternative source for NO, which plays a significant role in bacteria and plants [35]. In mammals, the oxygen-independent nitrite reductive pathway was implicated in hypoxic vasodilation [36–38] and control of blood pressure. Some studies showed that RBCs promote nitrite/NO-dependent vasodilation and inhibition of platelet aggregation under hypoxic conditions [7, 39, 40]. We recently showed that incubation of platelets with carbonic anhydrase purified from bovine RBCs in the presence of nitrite increases platelet cGMP content and induces VASP phosphorylation [41]. Therefore, it was important to test whether intact RBCs containing Hb in different status (oxyHb, deoxyHb, NO-Hb), with or without nitrite, and normal or deoxygenated platelets, can activate platelet sGC. Incubation of platelets with different concentrations of nitrite had no effect on PKG-dependent phosphorylation of VASP (Fig. 5a). These results on human platelets are consistent with a report on mouse platelets that nitrite triggers VASP phosphorylation only in the presence of PDE5 inhibitor [42]. Next, we co-incubated deoxygenated RBCs loaded with NO (deoxygenated RBCs) with deoxygenated platelets in the presence of increasing nitrite concentrations. Even under these conditions, we found no activation of platelet PKG (Fig. 5b). We tested all possible combinations of RBCs containing Hb in different status (oxyHb, deoxyHb, NO-Hb), with or without nitrite, and normal
or deoxygenated platelets, and found no evidence of activated platelet PKG (Fig. 5a, b, and other data not shown). To confirm that intact RBCs in the presence of nitrite do not produce NO, we incubated deoxygenated RBCs with nitrite and measured the activity of purified sGC. Anaerobic RBCs preincubated with 100 μM nitrite did not elevate purified sGC activity (Fig. 5c), which is consistent with strong NO-scavenging effect of RBCs. The same results were observed when the experiments were performed under aerobic conditions or with
10 μM nitrite (data not shown). To confirm the Hb status of RBCs, UV spectra were taken from each sample (Fig. 5d). Each spectrum corresponds to well-characterised Hb pattern of oxyHb (RBC), deoxyHb (RBC + Argon), NO-Hb (RBC + Argon + DEA-NO) and visible amount of metHb after 30 min incubation with DEA-NO [43].

**Endothelial cell-derived NO is the main source of platelet sGC activation**

In blood vessels, endothelial cells or circulating lymphocytes express NOS isoforms and may potentially be the source of NO for activation of platelet sGC/cGMP/PKG pathway. To evaluate the contribution of endothelial cells and lymphocytes, we co-incubated washed platelets with washed WBCs, or human umbilical vein endothelial cells (HUVECs) in the presence of L-arginine or L-NAME. Incubation of platelets with WBCs in the presence of L-arginine did not activate platelet PKG, however, NOS activity of WBCs was slightly increased by L-arginine and inhibited by L-NAME. It is likely that the amount of NO produced by WBCs in our experimental setting was not sufficient for activation of platelet sGC. In contrast, NO producted by HUVECs, which can be inhibited by L-NAME, strongly stimulates platelet sGC (Fig. 6) suggesting that endothelial cell-derived NO is the main source of platelet sGC activation. Our *in vitro* data are in good agreement with *in vivo* mouse models, where it was shown that eNOS of endothelial cells exerts a direct anti-thrombotic effects on platelets [44].

**Discussion**

The key role of RBCs in hypoxic vasodilation is well known. RBCs trigger sGC activation in the smooth muscle cells of the vessel wall that leads to vessel dilation. Few publications report that RBCs release NO during hypoxia, thus activating sGC. Several mechanisms were proposed to argue the NO carrying properties of RBCs/Hb. In one mechanism, Hb nitrosyl-heme adduct (NO-Hb) is regarded as a form of NO storage and carrier. NO reduced from nitrite by deoxyhemoglobin was considered as an explanation for hypoxic vasodilation [39, 40, 46]. However, this hypothesis was strongly criticized by others [15]. Strong NO scavenging properties of oxyhemoglobin in hypoxic condition is considered to be an important requirement for effective nitrite/RBCs-dependent NO generation or release. However, the link between RBCs and sGC activation is clearly missing because direct activation of sGC by NO or SNO released from RBCs is not experimentally shown. Nevertheless, until now, NO released from RBCs is considered as one of the established
mechanisms for RBC-induced hypoxic vasodilation and platelet inhibition. As RBCs-induced vasodilation might be controlled by other NO-independent mechanisms, we focused our study on the effects of RBC on platelet and purified sGC.

The main aim of our study was to establish whether RBCs could promote sGC activation by releasing NO/SNO under any possible conditions (in whole blood, under hypoxia, or even loaded with NO). To answer the question whether RBCs can activate sGC, we used our well-established model of NO-dependent sGC/cGMP/PKG activation in platelets and NO-mediated activation of purified sGC. Both these systems are highly sensitive to endogenous NO or SNO (GSNO, CysNO) and can be

---

**Fig. 5** Deoxygenated RBCs loaded with NO did not stimulate platelet PKG. **a** Western blot analysis of VASP\(^{5239}\) phosphorylation in platelets (3x10^8/ml) stimulated by DEA-NO (1 μM, 1 min), or incubated (10 min) with indicated concentrations of NaNO\(_2\). Experiment was done under argon. **b** Washed platelets and RBCs were deoxygenated by argon. RBCs (1x 10^8/ml) were washed 3 times by deoxygenated HEPES buffer, deoxygenated for additional 30 min and then incubated with DEA-NO (50 μM, 30 min) and added (1x10^8/ml in 10 μl) to platelets together with indicated concentrations of NaNO\(_2\) for 10 min. 10 μl of supernatant from the last wash was used as control for free Hb. Total VASP served as loading control. Shown are representative blots of four independent experiments. **c** sGC activity was measured under anaerobic conditions after incubation with 100 μM sodium nitrite and indicated amount of RBCs, as described in Method section. Data are presented as mean ± SEM, n = 4. **d** UV-visible spectra of oxyHb, deoxyHb, and deoxyHb loaded with NO. Hb spectra were taken from, oxygenated, deoxygenated (under argon), or deoxy-RBCs incubated for 15 and 30 min with 50 μM DEA-NO. Shown are representative spectra from four independent experiments.
used as a model to answer our question. Previous esti-
mations indicate a high number of molecules of sGC
(3700), PKG (3500) and VASP (44000) per single platelet
[47]. This high concentration of NO receptor and down-
stream signaling molecules makes platelets a very sensi-
tive model for detection of NO-dependent sGC
activation. PKA and PKG phosphorylate VASP at serines
157 and 239, respectively. In platelets, PKA and PKG
can equally phosphorylate both sites. We argue that if
RBCs-released NO/SNO is sufficient to induce vasodila-
tion, platelet sGC must be activated in the RBCs/platelet
suspension. Only one paper [7] showed more than 3
times increase of platelet cGMP concentration after
5 min incubation with 0.1 μM nitrate, and addition of
RBCs further increases cGMP more than 5 times. In this
paper, cGMP was measured by the enzyme-linked im-
munoblot assay from Cayman Chemicals. It is important to
mention that such a high cGMP increase (comparable
with NO donors effect) should undoubtedly activate
platelet PKG, which was not shown in this manuscript.
We specifically addressed this question and used several
cGMP determination assays from different suppliers,
however we were not able to reproduce their results.
Apparently, nitrite itself, and especially RBCs, interfere
with cGMP assays and, in some cases, might give
erroneous increase of platelet cGMP. After summarizing
results of eight experiments from different assays, we
did not detect any statistically significant cGMP accrual
in platelets incubated with nitrite and RBCs. It should
be mentioned that direct measurement of cGMP levels
in platelets, is complex and prone to artefacts, therefore
we did not include these data. This question has been
described in details in our recent review [48]. VASP
phosphorylation at Ser239 mediated by PKG, which is
even more sensitive than determination of cGMP itself
[49] is now accepted as one of the most commonly used
standards for evaluation of sGC/cGMP/PKG system ac-
tivation, especially in platelets. Therefore, in all our ex-
periments we used VASP Ser239 phosphorylation as a
readout of PKG activation mediated by cGMP increase.
We also tested whether RBCs activate purified sGC,
which is sensitive to low NO/SNO concentrations [29].
The experiments presented in the current report clearly
demonstrated that RBCs did not directly stimulate
purified sGC, under normoxic or hypoxic conditions or
in the presence of nitrite. Moreover, RBCs at physio-
logical concentration, completely inhibited sGC activa-
tion even by micromolar concentrations of NO donor
(Fig. 3b-e). Washed RBCs do not express detectable
amount of sGC, PKG, and VASP (Fig. 3a). Therefore, in
the experiments with RBCs/platelet suspension, the
phospho-VASP signal reflects the activation of sGC in
platelets. These experiments also show lack of platelet
sGC activation in the presence of RBCs and nitrite.
We should emphasize that thorough washing of RBCs is required because of the strong NO-scavenging by free Hb released from lysed RBCs. In about 1/3 of our experiments (these data were excluded) the supernatant of RBCs, which was always used as a control for free Hb contamination, inhibited NO-mediated VASP phosphorylation. It should be noted that in all papers describing inhibition of platelet activation by RBCs [5–7, 50], the results were assessed by aggregometry. In such experimental setting, RBCs-induced effects other than NO/cGMP-mediated platelet inhibition cannot be ruled out.

The experiments performed with whole blood (Fig. 2b) or with RBC/platelet suspension (Fig. 3d) demonstrated that stimulation/inhibition of NOS had no effect on platelet sGC activation. Our studies demonstrated that L-arginine-stimulated NO synthesis in WBCs is sufficient for sGC activation in WBCs, but not of platelet sGC (Fig. 6). However, these data do not exclude that under other experimental conditions WBC-produced NO could activate platelet sGC as well.

RBCs and platelets are the major cell populations in blood, however until now little is known about interactions between these two cell types. RBCs are involved in thrombus formation, but it is not clear which functional role they play in the development of thrombosis [51]. There are no indications in the literature concerning direct platelet/RBCs interactions. In vivo, circulating platelets are continuously exposed to activating and inhibiting factors. RBCs are one of the sources of platelet activating factors like ATP, ADP and Hb released from injured RBCs, which scavenges NO. Hemolysis of RBCs which leads to increase of free Hb, ADP and ATP in plasma is the main reason of platelet hyperreactivity in sickle cell disease patients [52, 53]. On the other hand, endothelial cells derived NO and prostacyclin are the major platelet inhibitory factors. A well-regulated equilibrium between these two opposing processes is important for the normal hemostasis and an impairment of this equilibrium will promote thrombotic or bleeding disorders.

Our experiments support the clinical data [1–3] that RBCs play only stimulatory role in platelets and they are not involved in platelet inhibitory pathways.

Conclusions
All our data demonstrated that RBCs act as strong NO scavengers and prevent NO-mediated inhibition of platelet. In all tested conditions, RBCs were not able to activate platelet or purified sGC.

Abbreviations
dehoxy-Hb, deoxyhemoglobin; Hb, hemoglobin; HUVECs, human umbilical vein endothelial cells; L-NAME, L-NN^2-nitroarginine methyl ester; L-NMA, NG-Methyl-L-arginine; L-SCNO, S-nitroso-L-cysteine; RBCs, red blood cells or erythrocytes; sGC, soluble guanylate cyclase; NO, nitric oxide; VASP, vasodilator Stimulated Phosphoprotein; NO-Hb, nitrosyl-heme adduct; oxy-Hb, oxyhemoglobin; met-Hb, methemoglobin; PKG, protein kinase G; PKA, protein kinase A; GSNO, S-nitroso glutathione; SNP, sodium nitroprusside

Acknowledgements
Not applicable.

Funding
The work was supported by Russian Fund of Fundamental Research (15-04-02438 to SG, IM, NR, JS), Grant-in-Aid (12GRNTI1930007 to EM); Gesellschaft für Thrombose- und Hämostaseforschung (GTH) to HS (Rudolf-Marx-Stipendium); German Research Foundation (DFG (FR 1725/5–1 to AF)); The Federal Ministry of Education and Research (BMBF (01E010003 to UW)), and Stiftung für Pathobiologie und Molekulare Diagnostik to HS and UW.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Authors’ contribution
SG, AF, EM, UW designed the work; SG, HS, LK, IM, JS, CR, NR, and AF were responsible for platelet/RBC/WBC experiments; IS and EM were responsible for purified sGC experiments; SG, AF, EM, and UW analyzed data and wrote the manuscript. All the authors read and approve the manuscript.

Author’s information
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics Approval and consent to participate
Blood was collected from healthy volunteers after obtaining informed consent, and according to our institutional guidelines and the Declaration of Helsinki. Our studies with human platelets were approved and reconfirmed (Sept. 24, 2008) by the local ethics committee of the University of Wuerzburg (Studies No. 67/92 and 114/04).

Author details
1 Institute of Clinical Biochemistry and Pathobiocemistry, University of Wuerzburg, Grombuehlstrasse 12, D-97080 Wuerzburg, Germany. 2 Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Thorez pr. 44, St, Petersburg 194223, Russia. 3 Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4 Institute of Physiology, University of Wuerzburg, Wuerzburg, Germany. 5 Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany. 6 Department of Internal Medicine, Division of Cardiology, University of Texas Houston Medical School, Houston, USA. 7 German Centre for Cardiovascular Research (DZHK) RheinMain, Mainz, Germany.

Received: 5 June 2016 Accepted: 1 August 2016 Published online: 11 August 2016

References
1. Anand A, Feffer SE. Hematocrit and bleeding time: an update. South Med J. 1994;87:299–301.
2. Boneu B, Fernandez F. The role of the hematocrit in bleeding. Transfus Med Rev. 1987;1:182–5.
3. Silvain J, Albat J, Kerneis M, Martin R, Firzi J, Vignalou JB, Barthelemy O, O’Connor SA, Luyt CE, Brechot N, et al. Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients: the TRANSFUSION-2 study (impact of transfusion of red blood cell on platelet activation and aggregation studied with flow cytometry used and light transmission aggregometry). J Am Coll Cardiol. 2014;63:1289–96.
4. Kumbhani DJ, Bhatt DL. Platelet activation: yet another strike against routine TRANSFUSION. Eur Heart J. 2010;31:2712–4.
5. Liu C, Wajn N, Liu X, Basu S, Janes J, Marvel M, Kegg C, Helm CC, Lee AN, Belanger AM, et al. Mechanisms of Human Erythrocytic Bioactivation of Nitrite. J Biol Chem. 2014;290(2):1281–94.

6. Park JW, Piknova B, Huang PL, Noguchi CT, Schechter AN. Effect of blood nitrite and nitrate levels on murine platelet function. PLoS One. 2013;8:e55699.

7. Sihirun S, Siwantastra T, Unchern S, Kittikool D, Noulsri E, Pattanapanyasat K, Fuchareon S, Piknova B, Schechter AN. Platelet inhibition by nitrite is dependent on erythrocytes and deoxygenation. PLoS One. 2012;7:e30380.

8. Akrawinthawong K, Park JW, Piknova B, Sibmooh N, Fuchareon S, Schechter AN. A flow cytometric analysis of the inhibition of platelet reactivity due to nitrite reduction by deoxygenated erythrocytes. PLoS One. 2014;9:e92435.

9. Wajn N, Liu X, Shetty P, Basu S, Wu H, Hogg N, Patel RP, Fudur CM, Kim-Shapiro DB. The role of red blood cell S-nitrosation in nitrite bioactivation and its modulation by leucine and glucose. Redox Biol. 2016;4:415–21.

10. Cortese-Krott MM, Rodriguez-Mateos A, Sansone R, Kuhnle GG, Thasian-Sivarajah S, Krenz T, Horn P, Crisp C, Wolters D, Heiss C, et al. Human red blood cells at work: identification and visualization of erythrocytic eNOS activity in health and disease. Blood. 2012;120:4229–37.

11. Kleinbongard P, Schulz R, Rassaf T, Lauer T, Dejam A, Jax T, Kumara I, Gharini P, Kabanova S, Ozuyaman B, et al. Red blood cells express a functional endothelial nitric oxide synthase. Blood. 2006;107:2943–51.

12. Schöner A, Beckmann B, Sandmann J, Kräskos D. Doubts concerning functional endothelial nitric oxide synthase in human erythrocytes. Blood. 2011;119:1322–3.

13. Isbell TS, Sun CW, Wu LC, Teng X, Vitturi DA, Branch BG, Keely CG, Peng N, Wyss JM, Ambalavanan N, et al. SNO-hemoglobin is not essential for red cell oxygen-dependent hypoxic vasodilation. Nat Med. 2008;14:773–7.

14. Liu Y, Sun CW, Honavar J, Townes T, Patel RP. Role of the b93cys, ATP and adenosine in red cell dependent hypoxic vasorelaxation. Int J Physiopathol Pharmacol. 2013;5:31–33.

15. Schwab DE, Stamlar JS, Singel DJ. Nitrite-methemoglobin inactivate for hypoxic vasodilation. Nat Chem Biol. 2009;5:366. author reply 367.

16. Walls JP. Nitric oxide and blood: a review. Transfus Med. 2005;15:11–1.

17. Tejero J, Basu V, Helms C, Hogg N, King SB, Kim-Shapiro DB, Gladwin MT. The nitric oxide response in plant-associated endosymbiotic bacteria. Biochim Biophys Acta. 2011;1809:1–5.

18. Allen BW, Stamlar JS, Plantadosi CA. Hemoglobin, nitric oxide and molecular mechanisms of hypoxic vasodilation. Trends Mol Med. 2009;15:452–60.

19. O0uwis BS, Stamlar RP, Patel RP. Nitric oxide formation versus scavenging: the red blood cell balancing act. J Physiol. 2012;590:4993–5000.

20. Gladwin MT, Kim-Shapiro DB. Vascular biology: Nitric oxide caught in traffic. Nature. 2012;491:444–5.

21. Crawford JH, Isbell TS, Huang Z, Shiva S, Chacko BK, Schechter AN, Darley-Umson VM, Kerby JD, Lang Jr JN, Kraus D, et al. Hypoxia, red blood cells, and nitrate regulate NO-dependent hypoxic vasodilation. Blood. 2006;107:5666–74.

22. Crawford JH, White CR, Patel RP. Vasoreactivity of S-nitrosohemoglobin: role of oxygen, heme, and NO oxidation states. Blood. 2003;101:4408–15.

23. Hanfle E, Boemere A, Zinke M, Gambaryan S, Schwarz A, Supuran CT, Tiskas D. Carbonic anhydrases are producers of S-nitrosothiols from inorganic nitrate and modulators of soluble guanylyl cyclase in human platelets. Amino Acids. 2016;48:1695–706.

24. Apostoli GL, Solomon A, Smallwood MJ, Winyard PG, Emerson M. Role of inorganic nitrate and nitrite in driving nitric oxide/cGMP-mediated inhibition of platelet aggregation in vitro and in vivo. J Thromb Haemost. 2014;12:11880–9.

25. Herold S, Rock G. Reactions of deoxy-, oxy-, and methemoglobin with carbon monoxide. Mechanistic studies of the S-nitrosothiol formation under different mixing conditions. J Biol Chem. 2003;278:6623–34.

26. Moore C, Tyrmirovs C, Emerson M. Functional regulation of vascular and platelet activity during thrombosis by nitric oxide and endothelial nitric oxide synthase. Thromb Haemost. 2010;104:342–9.

27. Ja L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohemoglobin: a dynamic activity of blood involved in vascular control. Nature. 1996;380:221–6.

28. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, et al. Nitric oxide production versus scavenging: do blood platelets produce nitric oxide from L-arginine or nitrite? Amino Acids. 2015;47:1779–93.

29. Mo E, Amin H, Bianco IH, Garthwaite J. The nitric oxide response in plant-associated endosymbiotic bacteria. Biochim Biophys Acta. 2003;1680:1–15.

30. Gambaryan S, Tiskas D. A review and discussion of platelet nitric oxide and nitrite oxidation of oxygen, heme, and NO oxidation states. Blood. 2003;101:4408–15.

31. Bunkhart JM, Faulde M, Gambaryan S, Radau S, Walter U, Martens L, Geiger J, Sickmann A, Zahedi RP. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of the catalytic subunit of protein kinase A from an NFkappaB-kappa8 complex. J Biol Chem. 2010;285:18352–63.

32. Lee YC, Martin E, Murad F. Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc Natl Acad Sci U S A. 2000;97:10763–8.

33. Martin E, Berka V, Bogatenkova E, Murad F, Tsai AL. Ligand selectivity of soluble guanylyl cyclase: effect of the hydrogen-bonding tyrosine in the distal heme pocket on binding of oxygen, nitric oxide, and carbon monoxide. J Biol Chem. 2006;281:27836–45.

34. Schultz G. General principles of assays for adenylate cyclase and guanylate cyclase activity. Methods Enzymol. 1974;38:115–25.

35. Corti P, Tejero J, Gladwin MT. Evidence mounts that red cells and deoxyhemoglobin can reduce nitrite to bioactive NO to mediate intravascular endocrine NO signaling: commentary on “Anti-platelet effects of dietary nitrate in healthy volunteers: involvement of cGMP and influence of sex.” Free Radic Biol Med. 2013;65:1518–20.

36. Martin E, Berka V, Schirman I, Tsai AL. Mechanism of binding of NO to soluble guanylyl cyclase: implication for the second NO binding to the heme proximal site. Biochemistry. 2012;51:2737–46.

37. Lipton AJ, Johnson MA, Macdonald T, Lieberman MW, Goozal D, Gaston B. S-nitrosothiols signal the ventilatory response to hypoxia. Nature. 2001;413:171–4.

38. Liu X, Miller MJ, Joshi MS, Sadowskova-Kowicka H, Clark DA, Lancaster Jr JR. Diffusion–limited reaction of free nitric oxide with erythrocytes. J Biol Chem. 1998;273:1909–13.

39. Cabrera JJ, Sanchez C, Gates AE, Bednar EJ, Mesta S, Richardson DJ, Delgado MJ. The nitric oxide response in plant-associated endosymbiotic bacteria. Biochim Biophys Acta. 2013;1829:1–5.
51. Tutwiler V, Litvinov R, Lozhkin AP, Peshkova AD, Lebedeva T, Ataullakhanov FI, Spiller KL, Cines DB, Weisel JW. Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood. Blood. 2016;127:149–59.

52. Helms CC, Marvel M, Zhao W, Stahle M, Vest R, Kato GJ, Lee JS, Christ G, Gladwin MT, Hantgan RR, Kim-Shapiro DB. Mechanisms of hemolysis-associated platelet activation. J Thromb Haemost. 2013;11:2148–54.

53. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007;110:2166–72.